Skip to content

Glaukos GKOS Free cash flow yield

Free cash flow yield at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
3%-2.1pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5%+0.6pp
AbbVie logo
AbbVieABBV
5.2%+1.0pp
Bausch + Lomb logo
Bausch + LombBLCO
-3.9%+1.7pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-13.1%+0.4pp
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-6.4%-3.0pp

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.91B+12.3%

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Calculated from Glaukos’s reported figures.

Based on trailing twelve months.

The official record: Glaukos’s 10-Q, filed May 1, 2025, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's free cash flow yield?
Glaukos (GKOS) reported free cash flow yield of -1% in Q1 2025.
How has Glaukos's free cash flow yield changed year-over-year?
Glaukos's free cash flow yield increased by 40.7% year-over-year, from -1.6% to -1%.
What is the long-term trend for Glaukos's free cash flow yield?
Over 2 years (2022 to 2024), Glaukos's free cash flow yield has grown at a -48.1% compound annual growth rate (CAGR), from -3% to -0.8%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.